{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:08:12Z","timestamp":1761102492853,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"research fund for cardiac rehabilitation and metabolic therapy","award":["CCA-CRMT-1707"],"award-info":[{"award-number":["CCA-CRMT-1707"]}]},{"name":"coronary microvascular disease innovation foundation","award":["2018-CCA-CMVD-04"],"award-info":[{"award-number":["2018-CCA-CMVD-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10557-021-07259-y","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T07:03:49Z","timestamp":1636700629000},"page":"497-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early Trimetazidine Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction Reduces Myocardial Infarction Size"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-5860","authenticated-orcid":false,"given":"Geng","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"A","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zichao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yundai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"issue":"5","key":"7259_CR1","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.3892\/mmr.2016.5773","volume":"14","author":"N Ma","year":"2016","unstructured":"Ma N, Bai J, Zhang W, Luo H, Zhang X, Liu D, et al. Trimetazidine protects against cardiac ischemia\/reperfusion injury via effects on cardiac miRNA21 expression, Akt and the Bcl2\/Bax pathway. Mol Med Rep. 2016;14(5):4216\u201322.","journal-title":"Mol Med Rep"},{"key":"7259_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.metabol.2015.10.022","volume":"65","author":"Z Liu","year":"2016","unstructured":"Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, et al. The protective effect of trimetazidine on myocardial ischemia\/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism. 2016;65:122\u201330.","journal-title":"Metabolism."},{"key":"7259_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00109-018-1664-3","volume":"96","author":"S Wu","year":"2018","unstructured":"Wu S, Chang G, Gao L, Jiang D, Wang L, Li G, et al. Trimetazidine protects against myocardial ischemia\/reperfusion injury by inhibiting excessive autophagy. J Mol Med (Berl). 2018;96:791\u2013806.","journal-title":"J Mol Med (Berl)"},{"key":"7259_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/FJC.0000000000000487","volume":"69","author":"Y Zhong","year":"2017","unstructured":"Zhong Y, Zhong P, He S, Zhang Y, Tang L, Ling Y, et al. Trimetazidine protects cardiomyocytes against hypoxia\/reoxygenation injury by promoting AMP-activated protein kinase-dependent autophagic flux. J Cardiovasc Pharmacol. 2017;69:389\u201397.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7259_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000446640","volume":"135","author":"Y Li","year":"2016","unstructured":"Li Y, Wang D, Hu C, Zhang P, Zhang D, Qin S. Efficacy and safety of adjunctive trimetazidine therapy for acute myocardial infarction: a systematic review and meta-analysis. Cardiology. 2016;135:188\u201395.","journal-title":"Cardiology."},{"key":"7259_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0003319718780551","volume":"70","author":"MS Kallistratos","year":"2019","unstructured":"Kallistratos MS, Poulimenos LE, Giannitsi S, Tsinivizov P, Manolis AJ. Trimetazidine in the prevention of tissue ischemic conditions. Angiology. 2019;70:291\u20138.","journal-title":"Angiology."},{"key":"7259_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijcard.2019.05.063","volume":"293","author":"M Marzilli","year":"2019","unstructured":"Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol. 2019;293:39\u201344.","journal-title":"Int J Cardiol"},{"key":"7259_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1023\/A:1007804007115","volume":"13","author":"P Di Pasquale","year":"1999","unstructured":"Di Pasquale P, Lo Verso P, Bucca V, Cannizzaro S, Scalzo S, Maringhini G, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther. 1999;13:423\u20138.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7259_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00392-013-0611-0","volume":"102","author":"JS Kim","year":"2013","unstructured":"Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J, et al. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean acute myocardial infarction registry. Clin Res Cardiol. 2013;102:915\u201322.","journal-title":"Clin Res Cardiol"},{"key":"7259_CR10","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/j.jacc.2010.01.049","volume":"55","author":"I Eitel","year":"2010","unstructured":"Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, et al. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol. 2010;55:2470\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"7259_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","volume":"74","author":"B Ibanez","year":"2019","unstructured":"Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. J Am Coll Cardiol. 2019;74:238\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"7259_CR12","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Authors\/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541\u2013619.","journal-title":"Eur Heart J"},{"key":"7259_CR13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","volume":"33","author":"J Lonborg","year":"2012","unstructured":"Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491\u20139.","journal-title":"Eur Heart J"},{"key":"7259_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.113.003653","volume":"128","author":"B Ibanez","year":"2013","unstructured":"Ibanez B, Macaya C, S\u00e1nchez-Brunete V, Pizarro G, Fern\u00e1ndez-Friera L, Mateos A, et al. Effect of early metoprolol on infarct size in ST-segment\u2013elevation myocardial infarction patients undergoing primary percutaneous coronary intervention the effect of metoprolol in Cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation. 2013;128:1495\u2013503.","journal-title":"Circulation."},{"key":"7259_CR15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1001\/jama.2012.421","volume":"307","author":"GW Stone","year":"2012","unstructured":"Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink J-HE, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trialIntracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817\u201326.","journal-title":"JAMA."},{"key":"7259_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jcin.2014.05.015","volume":"8","author":"SK White","year":"2015","unstructured":"White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, et al. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2015;8:178\u201388.","journal-title":"JACC Cardiovasc Interv"},{"key":"7259_CR17","doi-asserted-by":"crossref","unstructured":"Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY, et al. Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging. 2016;9:e005146.","DOI":"10.1161\/CIRCIMAGING.116.005146"},{"key":"7259_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jcmg.2017.01.008","volume":"10","author":"H Bulluck","year":"2017","unstructured":"Bulluck H, Hammond-Haley M, Weinmann S, Martinez-Macias R, Hausenloy DJ. Myocardial infarct size by CMR in clinical cardioprotection studies: insights from randomized controlled trials. J Am Coll Cardiol Img. 2017;10:230\u201340.","journal-title":"J Am Coll Cardiol Img"},{"key":"7259_CR19","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.116.025582","volume":"136","author":"R Fern\u00e1ndez-Jim\u00e9nez","year":"2017","unstructured":"Fern\u00e1ndez-Jim\u00e9nez R, Barreiro-P\u00e9rez M, Martin-Garc\u00eda A, S\u00e1nchez-Gonz\u00e1lez J, Ag\u00fcero J, Gal\u00e1n-Arriola C, et al. Dynamic edematous response of the human heart to myocardial infarction: implications for assessing myocardial area at risk and salvage. Circulation. 2017;136:1288\u2013300.","journal-title":"Circulation"},{"key":"7259_CR20","doi-asserted-by":"publisher","first-page":"e005841","DOI":"10.1161\/CIRCIMAGING.116.005841","volume":"10","author":"A Durante","year":"2017","unstructured":"Durante A, Laricchia A, Benedetti G, Esposito A, Margonato A, Rimoldi O, et al. Identification of high-risk patients after ST-segment-elevation myocardial infarction: comparison between angiographic and magnetic resonance parameters. Circ Cardiovasc Imaging. 2017;10:e005841.","journal-title":"Circ Cardiovasc Imaging"},{"key":"7259_CR21","doi-asserted-by":"publisher","first-page":"e006774","DOI":"10.1161\/CIRCIMAGING.117.006774","volume":"10","author":"T Stiermaier","year":"2017","unstructured":"Stiermaier T, Jobs A, de Waha S, Fuernau G, P\u00f6ss J, Desch S, et al. Optimized prognosis assessment in ST-segment-elevation myocardial infarction using a cardiac magnetic resonance imaging risk score. Circ Cardiovasc Imaging. 2017;10:e006774.","journal-title":"Circ Cardiovasc Imaging"},{"key":"7259_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.ajem.2017.05.024","volume":"35","author":"R Li","year":"2017","unstructured":"Li R, Tang X, Jing Q, Wang Q, Yang M, Han X, et al. The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI. Am J Emerg Med. 2017;35:1657\u201361.","journal-title":"Am J Emerg Med"},{"key":"7259_CR23","first-page":"58","volume":"5","author":"M Shehata","year":"2014","unstructured":"Shehata M. Cardioprotective effects of oral trimetazidine in diabetic patients with anterior wall myocardial infarction treated with thrombolysis. Cardiol Res. 2014;5:58\u201367.","journal-title":"Cardiol Res"},{"key":"7259_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4070\/kcj.2013.43.7.462","volume":"43","author":"S Demirelli","year":"2013","unstructured":"Demirelli S, Karakelleoglu S, Gundogdu F, Tas MH, Kaya A, Duman H, et al. The impact of trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. Korean Circ J. 2013;43:462\u20137.","journal-title":"Korean Circ J"},{"key":"7259_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","volume":"396","author":"R Ferrari","year":"2020","unstructured":"Ferrari R, Ford I, Fox K, Challeton JP, Correges A, Tendera M, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396:830\u20138.","journal-title":"Lancet."},{"key":"7259_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1053\/euhj.1999.2439","volume":"21","author":"The EMIP-FR Group","year":"2000","unstructured":"The EMIP-FR Group. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. Eur Heart J. 2000;21:1537\u201346.","journal-title":"Eur Heart J"},{"key":"7259_CR27","doi-asserted-by":"publisher","first-page":"41B","DOI":"10.1016\/S0002-9149(99)80461-5","volume":"76","author":"MI Noble","year":"1995","unstructured":"Noble MI, Belcher PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol. 1995;76:41B\u20134B.","journal-title":"Am J Cardiol"},{"key":"7259_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.atherosclerosis.2014.10.091","volume":"237","author":"T Senturk","year":"2014","unstructured":"Senturk T, Cavun S, Avci B, Yermezler A, Serdar Z, Savci V. Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury. Atherosclerosis. 2014;237:760\u20136.","journal-title":"Atherosclerosis."},{"key":"7259_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.fjc.0000164091.81198.a3","volume":"46","author":"I Tritto","year":"2005","unstructured":"Tritto I, Wang P, Kuppusamy P, Giraldez R, Zweier JL, Ambrosio G. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol. 2005;46:89\u201398.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7259_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000369246","volume":"130","author":"YC Liu","year":"2015","unstructured":"Liu YC, Li L, Su Q, Liu T, Tang ZL. Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a swine model of coronary microembolization. Cardiology. 2015;130:130\u20136.","journal-title":"Cardiology."},{"key":"7259_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/hrt.2006.107524","volume":"93","author":"L Bonello","year":"2007","unstructured":"Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007;93:703\u20137.","journal-title":"Heart."},{"key":"7259_CR32","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ijcard.2015.11.060","volume":"203","author":"YM Lopatin","year":"2016","unstructured":"Lopatin YM, Rosano GMC, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LHW, et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 2016;203:909\u201315.","journal-title":"Int J Cardiol"},{"key":"7259_CR33","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jacc.2011.11.027","volume":"59","author":"L Zhang","year":"2012","unstructured":"Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59:913\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"7259_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/hrt.2010.208751","volume":"97","author":"D Gao","year":"2011","unstructured":"Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97:278\u201386.","journal-title":"Heart."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07259-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07259-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07259-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T07:06:08Z","timestamp":1683356768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07259-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["7259"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07259-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"6 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was registered on  (registration number: NCT02826616). The study protocol was approved by the Ethics Committee of Chinese PLA General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}